Hydrocortisone: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
HAS (France), NYE METODER (Norway) and PBAC (Australia) recommended or restricted hydrocortisone, while CIPM (Spain) did not recommend it.
On the same population the two systems disagree outright: PBAC (Australia) recorded recommended for “Adrenal Insufficiency”, while SMC (Scotland) recorded not recommended for “for the treatment of adrenal insufficiency in adults.”.
NYE METODER (Norway) has been easier on hydrocortisone than on its own caseload: it refused 0 of 5 decisive submissions here (0%), against a base rate of 37% across everything it has assessed.
The file has been open for more than a decade: 22.2 years separate the first record, 14 Jun 2004 at TLV (Sweden), from the most recent, 20 Sep 2026 at NYE METODER (Norway).
SMC (Scotland) changed its position: not recommended on 12 Dec 2016, restricted by 8 Oct 2018, after a resubmission.
Every one of the eight highest-volume agencies in this archive has a record for hydrocortisone.
Not every gap is a refusal: for hydrocortisone, 2 were withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 6 of 32 records date from 2023 or later.
4 distinct indication wordings are recorded for hydrocortisone by the agencies that label one in English (AWMSG, PBAC and SMC).
3 of these 32 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
TLV (Sweden) was first to assess hydrocortisone, on 14 Jun 2004; PBAC (Australia) did not open a file until 2021 — an unusually long tail of 17.1 years between the earliest and latest system to look at it.
The record arrives in waves: 7 separate years each carry two or more decisions, spread across 17 years in total.
7 of the 10 agencies here assessed hydrocortisone more than once, HAS (France) most often at 7 entries — repeat review is the norm for this molecule rather than the exception.
10 of the 18 agencies in this archive hold a record for hydrocortisone.
The full ledger for hydrocortisone reads 15 recommended, 8 not recommended, 3 restricted and 2 withdrawn, with 4 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CIPM (Spain) | 24 Sep 2025 | Indicación terapéutica autorizada: Oftalmolosa Cusí Hidrocortisona está indicado en el tratamiento de procesos alérgicos… | excluded from SNS provision · art. 92 e | source |
| PBAC (Australia) | 2023 | Adrenal insufficiency in children aged 6 or younger | Recommended | source |
| NYE METODER (Norway) | 20 Mar 2022 | Behandling av medfødt binyrebarkhyperplasi hos ungdom ≥12 år og voksne | introduced with conditions | source |
| TLV (Sweden) | 17 Dec 2021 | Efmody ingår inte i högkostnadsskyddet | rejection or exclusion | source |
| HAS (France) | 9 Sep 2009 | Listing (Transparency Committee) | ASMR V | source |
27 further decisions for hydrocortisone, across 10 agencies, are not shown here. They include the most recent record on file, 20 Sep 2026 from NYE METODER (Norway); its outcome is in the subscriber dataset. They link to 23 further source documents.
Related molecules
- deflazacort — same ATC class H02A — Systemic corticosteroids
- vamorolone — same ATC class H02A — Systemic corticosteroids
- fludrocortisone — same ATC class H02A — Systemic corticosteroids
- guselkumab — also decided by NYE METODER in 2026Q3
- ponatinib — also decided by NYE METODER in 2026Q3
- bimekizumab — also decided by NYE METODER in 2026Q3
Coverage: 32 decisions for hydrocortisone from 10 agencies, 2004 to 2026. Data to 7 Sep 2026. ATC class H02A — Systemic corticosteroids. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.